Results 211 to 220 of about 14,359 (249)
Some of the next articles are maybe not open access.

Substitution-Free Hemodiafiltration

ASAIO Journal, 2012
Hemodiafiltration (HDF) has been reported to deliver better dialysis outcomes in patients with end-stage renal disease. Technical advances now allow online-based HDF to be used on a clinical basis. However, HDF is being performed at a limited rate because of the requirement of exogenous fluid infusion, which causes safety and cost issues.
Kyungsoo, Lee   +2 more
openaire   +2 more sources

Hemodiafiltration in developing countries

Seminars in Dialysis, 2022
AbstractHemodiafiltration (HDF) is a promising kidney replacement therapy modality for patients with end‐stage kidney disease. The principle of uremic toxin clearance by combining convection and diffusion can lead to greater benefits compared to conventional hemodialysis. Evidence is building that supports the advantages of HDF with short‐term outcomes
Prit, Kusirisin, Nattachai, Srisawat
openaire   +2 more sources

Inflammation and Hemodiafiltration

2007
Atherosclerosis and the subsequent cardiovascular diseases are the most important causes of morbidity and mortality in patients with chronic kidney disease (CKD). CKD atherosclerosis is closely associated with the inflammatory status which is chronically present in these patients.
Rafael, Ramirez   +2 more
openaire   +2 more sources

Basic physics of hemodiafiltration

Seminars in Dialysis, 2022
AbstractStandard high‐flux hemodialysis (HD) clears urea very efficiently but is less efficient at clearing uremic toxins with larger molecule size, which diffuse more slowly. Hemodiafiltration (HDF) provides much higher convection rates, thereby reliably increasing the clearance of these larger toxins.
Leszek Pstras   +2 more
openaire   +2 more sources

Mixed-Dilution Hemodiafiltration

2007
Mixed-dilution hemodiafiltration (mixed HDF) controlled by the transmembrane pressure (TMP) feedback, improves the depurative capacity of the more traditional HDF techniques by fully exploiting the convective mechanism of small- and middle-molecular-weight solute removal.
Luciano A, Pedrini, Simona, Zerbi
openaire   +2 more sources

Paired Hemodiafiltration

2007
The feasibility of obtaining low-cost high-quality online reinjection fluids was fi rst explored almost 30 years ago, but regulatory conservatism delayed adoption of the technique for almost 20 years. Online treatments are now commonplace in Europe. The competitive advantages of this treatment modality compared to standard convective treatments include
openaire   +2 more sources

Push/Pull Hemodiafiltration

2007
Push/pull hemodiafiltration is characterized by alternate filtration and backfiltration, while sterile pyrogen-free dialysate is flowing through a hemodiafilter. During the filtration phase, uremic substances are eliminated not only by diffusive, but also by convective transport. During the backfiltration phase, dialysate is quickly pushed to the blood
Toru, Shinzato, Kenji, Maeda
openaire   +2 more sources

Evolution of Hemodiafiltration

2007
The evolution of hemodiafiltration (HDF) has become possible by the advances in the construction of dialysis membranes. The availability of a high-flux membrane, partially hydrophilic with high sieving coefficients and a reduced wall thickness has made it possible to conveniently combine diffusion and convection for blood purification.
openaire   +3 more sources

Medication and Hemodiafiltration

2015
The amount of drug clearance during online hemodiafiltration (HDF) is determined by (1) the pharmacokinetic properties of a drug defined by its absorption, distribution, metabolism and elimination (ADME) characteristics, (2) dialysis characteristics, including membrane properties, treatment time and blood-, dialysate-and ultrafiltration flow rates, and
Zandvliet, Anthe S.   +2 more
openaire   +2 more sources

Inflammatory Pattern in Hemodiafiltration

2008
Chronic inflammation may play an important role in early morbidity and mortality in hemodialysis (HD) patients. Interleukin-6 (IL-6) production is enhanced in long-term HD patients and this activated phase response has been shown to be a predictor of cardiovascular disease in the uremic syndrome as well as in the general population.
PANICHI, VINCENZO   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy